Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Net Cash Flow: 2020-2025

Historic Net Cash Flow for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to $40.4 million.

  • Silence Therapeutics' Net Cash Flow rose 172.41% to $40.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 110.78%. This contributed to the annual value of $52.5 million for FY2024, which is 2866.70% up from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' Net Cash Flow is $40.4 million, which was up 272.96% from -$23.4 million recorded in Q2 2025.
  • Silence Therapeutics' Net Cash Flow's 5-year high stood at $74.0 million during Q1 2024, with a 5-year trough of -$56.7 million in Q1 2025.
  • Over the past 3 years, Silence Therapeutics' median Net Cash Flow value was -$9.1 million (recorded in 2023), while the average stood at $785,541.
  • The largest annual percentage gain for Silence Therapeutics' Net Cash Flow in the last 5 years was 16,706.50% (2022), contrasted with its biggest fall of 1,253.11% (2022).
  • Over the past 5 years, Silence Therapeutics' Net Cash Flow (MRQ) stood at $3.0 million in 2021, then tumbled by 1,253.11% to -$34.9 million in 2022, then skyrocketed by 72.37% to -$9.6 million in 2023, then soared by 499.44% to $38.5 million in 2024, then rose by 4.78% to $40.4 million in 2025.
  • Its last three reported values are $40.4 million in Q3 2025, -$23.4 million for Q2 2025, and -$56.7 million during Q1 2025.